1
|
Powell J, Mann CA, Toth PD, Nolan S, Steinert A, Ove C, Seffernick JT, Wozniak DJ, Kebriaei R, Lindert S, Osheroff N, Yalowich JC, Mitton-Fry MJ. Development of Novel Bacterial Topoisomerase Inhibitors Assisted by Computational Screening. ACS Med Chem Lett 2024; 15:1287-1297. [PMID: 39140037 PMCID: PMC11318591 DOI: 10.1021/acsmedchemlett.4c00162] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2024] [Revised: 06/16/2024] [Accepted: 06/20/2024] [Indexed: 08/15/2024] Open
Abstract
Multidrug-resistant bacterial infections pose an ever-evolving threat to public health. Since the outset of the antibacterial age, bacteria have developed a multitude of diverse resistance mechanisms that suppress the effectiveness of current therapies. New drug entities, such as Novel Bacterial Topoisomerase Inhibitors (NBTIs), can circumvent this major issue. A computational docking model was employed to predict the binding to DNA gyrase of atypical NBTIs with novel pharmacophores. Synthesis of NBTIs based on computational docking and subsequent antibacterial evaluation against both Gram-positive and Gram-negative bacteria yielded congeners with outstanding anti-staphylococcal activity and varying activity against select Gram-negative pathogens.
Collapse
Affiliation(s)
- Joshua
W. Powell
- Division
of Medicinal Chemistry and Pharmacognosy, Department of Chemistry and Biochemistry, Microbial Infection
and Immunity, Division of Outcomes and Translational Sciences, Department of Microbiology, and Division of Pharmaceutics
and Pharmacology, The Ohio State University, Columbus, Ohio 43210, United States
| | - Chelsea A. Mann
- Division
of Medicinal Chemistry and Pharmacognosy, Department of Chemistry and Biochemistry, Microbial Infection
and Immunity, Division of Outcomes and Translational Sciences, Department of Microbiology, and Division of Pharmaceutics
and Pharmacology, The Ohio State University, Columbus, Ohio 43210, United States
| | - Paul D. Toth
- Division
of Medicinal Chemistry and Pharmacognosy, Department of Chemistry and Biochemistry, Microbial Infection
and Immunity, Division of Outcomes and Translational Sciences, Department of Microbiology, and Division of Pharmaceutics
and Pharmacology, The Ohio State University, Columbus, Ohio 43210, United States
| | - Sheri Nolan
- Division
of Medicinal Chemistry and Pharmacognosy, Department of Chemistry and Biochemistry, Microbial Infection
and Immunity, Division of Outcomes and Translational Sciences, Department of Microbiology, and Division of Pharmaceutics
and Pharmacology, The Ohio State University, Columbus, Ohio 43210, United States
| | - Anja Steinert
- Division
of Medicinal Chemistry and Pharmacognosy, Department of Chemistry and Biochemistry, Microbial Infection
and Immunity, Division of Outcomes and Translational Sciences, Department of Microbiology, and Division of Pharmaceutics
and Pharmacology, The Ohio State University, Columbus, Ohio 43210, United States
| | - Clarissa Ove
- Division
of Medicinal Chemistry and Pharmacognosy, Department of Chemistry and Biochemistry, Microbial Infection
and Immunity, Division of Outcomes and Translational Sciences, Department of Microbiology, and Division of Pharmaceutics
and Pharmacology, The Ohio State University, Columbus, Ohio 43210, United States
| | - Justin T. Seffernick
- Division
of Medicinal Chemistry and Pharmacognosy, Department of Chemistry and Biochemistry, Microbial Infection
and Immunity, Division of Outcomes and Translational Sciences, Department of Microbiology, and Division of Pharmaceutics
and Pharmacology, The Ohio State University, Columbus, Ohio 43210, United States
| | - Daniel J. Wozniak
- Division
of Medicinal Chemistry and Pharmacognosy, Department of Chemistry and Biochemistry, Microbial Infection
and Immunity, Division of Outcomes and Translational Sciences, Department of Microbiology, and Division of Pharmaceutics
and Pharmacology, The Ohio State University, Columbus, Ohio 43210, United States
| | - Razieh Kebriaei
- Division
of Medicinal Chemistry and Pharmacognosy, Department of Chemistry and Biochemistry, Microbial Infection
and Immunity, Division of Outcomes and Translational Sciences, Department of Microbiology, and Division of Pharmaceutics
and Pharmacology, The Ohio State University, Columbus, Ohio 43210, United States
| | - Steffen Lindert
- Division
of Medicinal Chemistry and Pharmacognosy, Department of Chemistry and Biochemistry, Microbial Infection
and Immunity, Division of Outcomes and Translational Sciences, Department of Microbiology, and Division of Pharmaceutics
and Pharmacology, The Ohio State University, Columbus, Ohio 43210, United States
| | - Neil Osheroff
- Department of Biochemistry and Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States
| | - Jack C. Yalowich
- Division
of Medicinal Chemistry and Pharmacognosy, Department of Chemistry and Biochemistry, Microbial Infection
and Immunity, Division of Outcomes and Translational Sciences, Department of Microbiology, and Division of Pharmaceutics
and Pharmacology, The Ohio State University, Columbus, Ohio 43210, United States
| | - Mark J. Mitton-Fry
- Division
of Medicinal Chemistry and Pharmacognosy, Department of Chemistry and Biochemistry, Microbial Infection
and Immunity, Division of Outcomes and Translational Sciences, Department of Microbiology, and Division of Pharmaceutics
and Pharmacology, The Ohio State University, Columbus, Ohio 43210, United States
| |
Collapse
|
2
|
Ampomah-Wireko M, Chen S, Li R, Gao C, Wang M, Qu Y, Kong H, Nininahazwe L, Zhang E. Recent advances in the exploration of oxazolidinone scaffolds from compound development to antibacterial agents and other bioactivities. Eur J Med Chem 2024; 269:116326. [PMID: 38513340 DOI: 10.1016/j.ejmech.2024.116326] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2024] [Revised: 02/26/2024] [Accepted: 03/10/2024] [Indexed: 03/23/2024]
Abstract
Bacterial infections cause a variety of life-threatening diseases, and the continuous evolution of drug-resistant bacteria poses an increasing threat to current antimicrobial regimens. Gram-positive bacteria (GPB) have a wide range of genetic capabilities that allow them to adapt to and develop resistance to practically all existing antibiotics. Oxazolidinones, a class of potent bacterial protein synthesis inhibitors with a unique mechanism of action involving inhibition of bacterial ribosomal translation, has emerged as the antibiotics of choice for the treatment of drug-resistant GPB infections. In this review, we discussed the oxazolidinone antibiotics that are currently on the market and in clinical development, as well as an updated synopsis of current advances on their analogues, with an emphasis on innovative strategies for structural optimization of linezolid, structure-activity relationship (SAR), and safety properties. We also discussed recent efforts aimed at extending the activity of oxazolidinones to gram-negative bacteria (GNB), antitumor, and coagulation factor Xa. Oxazolidinone antibiotics can accumulate in GNB by a conjugation to siderophore-mediated β-lactamase-triggered release, making them effective against GNB.
Collapse
Affiliation(s)
- Maxwell Ampomah-Wireko
- School of Pharmaceutical Sciences, Key Laboratory of Advanced Pharmaceutical Technology, Ministry of Education of China, Zhengzhou University, Zhengzhou 450001, PR China
| | - Shengcong Chen
- School of Pharmaceutical Sciences, Key Laboratory of Advanced Pharmaceutical Technology, Ministry of Education of China, Zhengzhou University, Zhengzhou 450001, PR China
| | - Ruirui Li
- School of Pharmaceutical Sciences, Key Laboratory of Advanced Pharmaceutical Technology, Ministry of Education of China, Zhengzhou University, Zhengzhou 450001, PR China
| | - Chen Gao
- School of Pharmaceutical Sciences, Key Laboratory of Advanced Pharmaceutical Technology, Ministry of Education of China, Zhengzhou University, Zhengzhou 450001, PR China
| | - Meng Wang
- School of Pharmaceutical Sciences, Key Laboratory of Advanced Pharmaceutical Technology, Ministry of Education of China, Zhengzhou University, Zhengzhou 450001, PR China
| | - Ye Qu
- School of Pharmaceutical Sciences, Key Laboratory of Advanced Pharmaceutical Technology, Ministry of Education of China, Zhengzhou University, Zhengzhou 450001, PR China
| | - Hongtao Kong
- School of Pharmaceutical Sciences, Key Laboratory of Advanced Pharmaceutical Technology, Ministry of Education of China, Zhengzhou University, Zhengzhou 450001, PR China
| | - Lauraine Nininahazwe
- School of Pharmaceutical Sciences, Key Laboratory of Advanced Pharmaceutical Technology, Ministry of Education of China, Zhengzhou University, Zhengzhou 450001, PR China
| | - En Zhang
- School of Pharmaceutical Sciences, Key Laboratory of Advanced Pharmaceutical Technology, Ministry of Education of China, Zhengzhou University, Zhengzhou 450001, PR China; Pingyuan Laboratory (Zhengzhou University), PR China.
| |
Collapse
|
3
|
Cumming JG, Kreis L, Kühne H, Wermuth R, Vercruysse M, Cantrill C, Bissantz C, Qiu H, Kramer C, Andreotti D, Fossati G. Novel Indane-Containing NBTIs with Potent Anti-Gram-Negative Activity and Minimal hERG Inhibition. ACS Med Chem Lett 2023; 14:1791-1799. [PMID: 38116438 PMCID: PMC10726470 DOI: 10.1021/acsmedchemlett.3c00422] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2023] [Revised: 11/02/2023] [Accepted: 11/07/2023] [Indexed: 12/21/2023] Open
Abstract
Novel bacterial topoisomerase inhibitors (NBTIs) make up a promising new class of antibiotics with the potential to combat the growing threat of antimicrobial resistance. Two key challenges in the development of NBTIs have been to obtain broad spectrum activity against multidrug-resistant Gram-negative bacteria and to diminish inhibition of the hERG cardiac ion channel. Here we report the optimization of a series of NBTIs bearing a novel indane DNA intercalating moiety. The addition of a basic, polar side chain connected to the indane by an ether or an N-linked secondary amide linkage together with a lipophilicity-lowering modification of the enzyme binding moiety led to compounds such as 2a and 2g which showed excellent broad spectrum potency and minimal hERG inhibition. Compound 2a demonstrated robust bactericidal in vivo activity in a mouse lung infection model with the strain P. aeruginosa ATCC 27853 which is resistant to several clinically relevant antibiotics. Rodent pharmacokinetic studies with 2a revealed an unusual profile characterized by rapid tissue distribution and a prolonged, flat terminal phase. This profile precluded further development of these compounds as potential new antibiotics.
Collapse
Affiliation(s)
- John G. Cumming
- Roche
Pharma Research & Early Development, F. Hoffmann-La Roche Ltd., CH-4070 Basel, Switzerland
| | - Lukas Kreis
- Roche
Pharma Research & Early Development, F. Hoffmann-La Roche Ltd., CH-4070 Basel, Switzerland
| | - Holger Kühne
- Roche
Pharma Research & Early Development, F. Hoffmann-La Roche Ltd., CH-4070 Basel, Switzerland
| | - Roger Wermuth
- Roche
Pharma Research & Early Development, F. Hoffmann-La Roche Ltd., CH-4070 Basel, Switzerland
| | - Maarten Vercruysse
- Roche
Pharma Research & Early Development, F. Hoffmann-La Roche Ltd., CH-4070 Basel, Switzerland
| | - Carina Cantrill
- Roche
Pharma Research & Early Development, F. Hoffmann-La Roche Ltd., CH-4070 Basel, Switzerland
| | - Caterina Bissantz
- Roche
Pharma Research & Early Development, F. Hoffmann-La Roche Ltd., CH-4070 Basel, Switzerland
| | - Hongxia Qiu
- China
Innovation Center of Roche, Roche R&D
Center (China) Ltd., Shanghai 201203, China
| | - Christian Kramer
- Roche
Pharma Research & Early Development, F. Hoffmann-La Roche Ltd., CH-4070 Basel, Switzerland
| | | | | |
Collapse
|
4
|
Phelps HA, Kuhn M, Lu Y, Vibhute S, Watts JL, Mitton-Fry MJ. Antibacterial activity of novel bacterial topoisomerase inhibitors against key veterinary pathogens. Vet Microbiol 2023; 284:109840. [PMID: 37531840 DOI: 10.1016/j.vetmic.2023.109840] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2022] [Revised: 07/07/2023] [Accepted: 07/28/2023] [Indexed: 08/04/2023]
Abstract
Multidrug-resistant bacteria infect companion animals and livestock in addition to their devastating impact on human health. Novel Bacterial Topoisomerase Inhibitors (NBTIs) with excellent activity against Gram-positive bacteria have previously been identified as promising new antibacterial agents. Herein, we evaluate the antibacterial activity of these NBTIs against a variety of important veterinary pathogens and demonstrate outstanding in vitro activity, especially against staphylococci.
Collapse
Affiliation(s)
- Hilary A Phelps
- Global Therapeutics, Anti-Infectives Research, Zoetis, 333 Portage Street, Kalamazoo, MI 49007, United States
| | - Michael Kuhn
- Global Therapeutics, Anti-Infectives Research, Zoetis, 333 Portage Street, Kalamazoo, MI 49007, United States
| | - Yanran Lu
- Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, 500 West 12th Avenue, Columbus, OH 43210, United States
| | - Sandip Vibhute
- Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, 500 West 12th Avenue, Columbus, OH 43210, United States
| | - Jeffrey L Watts
- Global Therapeutics, Anti-Infectives Research, Zoetis, 333 Portage Street, Kalamazoo, MI 49007, United States
| | - Mark J Mitton-Fry
- Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, 500 West 12th Avenue, Columbus, OH 43210, United States.
| |
Collapse
|